~~<i id='2DB5116670'><strike id='2DB5116670'><tt id='2DB5116670'><pre id='2DB5116670'></pre></tt></strike></i>~~

Home» Wikipedia» comprehensive

comprehensive

author：knowledge 2025-09-30 07:37:23 Page View：88524

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： UpToDate has a racism problem: Dr. Stanley Goldfarb
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Use doctors trained outside the U.S. to ease the physician shortage

AdobeThislegislativesession,Gov.BillLeemadehistorybysigningabillthatmakesTennesseethefirststateinthe

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Security flaws in third

AdobeInthelastyear,cyberattacksonhospitalshavesurged,puttingaspotlightontheneedtoprotectpatients’hea